Bryan, Garnier & Co Raises Oncimmune (ONC) Price Target to GBX 168

Oncimmune (LON:ONC) had its target price upped by research analysts at Bryan, Garnier & Co from GBX 154 ($2.13) to GBX 168 ($2.32) in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the stock. Bryan, Garnier & Co’s target price would indicate a potential upside of 15.27% from the company’s previous close.

Separately, Berenberg Bank began coverage on shares of Oncimmune in a research report on Friday, January 19th. They set a “buy” rating and a GBX 169 ($2.33) price objective for the company.

Oncimmune (LON ONC) traded up GBX 0.75 ($0.01) on Tuesday, reaching GBX 145.75 ($2.01). 18,179 shares of the company traded hands, compared to its average volume of 40,831. Oncimmune has a 1-year low of GBX 100 ($1.38) and a 1-year high of GBX 150 ($2.07). The company has a market capitalization of $87.74 and a PE ratio of -1,457.50.

Oncimmune (LON:ONC) last posted its quarterly earnings data on Tuesday, February 13th. The company reported GBX (5.70) (($0.08)) earnings per share for the quarter. Oncimmune had a negative return on equity of 81.75% and a negative net margin of 2,521.78%. The firm had revenue of GBX 8 million for the quarter.

TRADEMARK VIOLATION NOTICE: “Bryan, Garnier & Co Raises Oncimmune (ONC) Price Target to GBX 168” was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at

Oncimmune Company Profile

Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types.

Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with's FREE daily email newsletter.

Leave a Reply